Changes in prescription and over-the-counter medication and dietary supplement use among older adults in the United States, 2005 vs 2011

JAMA Internal Medicine

Volumn 176, Issue 4, 2016, Pages 473-482

  Qato, Dima M ^a   Wilder, Jocelyn ^a   Schumm, L Philip ^b   Gillet, Victoria ^c   Alexander, G Caleb ^d  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; FISH OIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NON PRESCRIPTION DRUG; OMEGA 3 FATTY ACID; PRESCRIPTION DRUG;

ADULT; AGED; DIET SUPPLEMENTATION; DRUG INTERACTION; FEMALE; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK; UNITED STATES; COHORT ANALYSIS; DIETARY SUPPLEMENT; INDEPENDENT LIVING; LONGITUDINAL STUDY; MIDDLE AGED; POLYPHARMACY; PROSPECTIVE STUDY; UTILIZATION; VERY ELDERLY;

AGED; AGED, 80 AND OVER; COHORT STUDIES; DIETARY SUPPLEMENTS; DRUG INTERACTIONS; FEMALE; HUMANS; INDEPENDENT LIVING; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NONPRESCRIPTION DRUGS; POLYPHARMACY; PRESCRIPTION DRUGS; PREVALENCE; PROSPECTIVE STUDIES; UNITED STATES;

EID: 84962675169     PISSN: 21686106     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamainternmed.2015.8581     Document Type: Review

References (47)

1. Gu Q, Dillon CF, Burt VL. Prescription drug use continues to increase: U.S. prescription drug data for 2007-2008. NCHS Data Brief. 2010;(42):1-8.
2. Wolff JL, Starfield B, Anderson G. Prevalence, expenditures, and complications of multiple chronic conditions in the elderly. Arch Intern Med. 2002;162(20):2269-2276.
3. American Geriatrics Society 2012 Beers Criteria Update Expert Panel. American Geriatrics Society updated Beers Criteria for potentially inappropriate medication use in older adults. J AmGeriatr Soc. 2012;60(4):616-631.
4. Budnitz DS, Pollock DA,Weidenbach KN, Mendelsohn AB, Schroeder TJ, Annest JL. National surveillance of emergency department visits for outpatient adverse drug events. JAMA. 2006;296 (15):1858-1866.
5. Hilmer SN, Gnjidic D. The effects of polypharmacy in older adults. Clin Pharmacol Ther. 2009;85(1):86-88.
6. LeissW, Méan M, Limacher A, et al. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med. 2015;30(1): 17-24.
7. Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. 2011;365 (21):2002-2012.
8. Qato DM, Alexander GC, Conti RM, Johnson M, Schumm P, Lindau ST. Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300(24):2867-2878.
9. Briesacher BA, Zhao Y, Madden JM, et al. Medicare Part D and changes in prescription drug use and cost burden: national estimates for the Medicare population, 2000 to 2007. Med Care. 2011;49(9):834-841.
10. Aitken M, Berndt ER, Cutler DM. Prescription drug spending trends in the United States: looking beyond the turning point. Health Aff (Millwood). 2009;28(1):w151-w160.
11. Alldredge BK, Kayser SR. Bending the curve toward increased use of generic drugs. JAMA Intern Med. 2013;173(3):233-234.
12. IMS Institute for Healthcare Informatics. The use of medicines in the United States: review of 2011. https://www.imshealth.com/files/web/IMSH %20Institute/Reports/The%20Use%20of %20Medicines%20in%20the%20United %20States%202011/IHII-Medicines-in-U.S-Report -2011.pdf. Accessed February 1, 2016.
13. SimonsonW. Implications of over-the-counter proton pump inhibitors for patient counseling by pharmacists. Am J Ther. 2013;20(6):676-684.
14. Kelley BJ, Glasser S. Cognitive effects of statin medications. CNS Drugs. 2014;28(5):411-419.
15. Dormuth CR, Filion KB, Paterson JM, et al; Canadian Network for Observational Drug Effect Studies Investigators. Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases. BMJ. 2014;348: g3244.
16. Desai CS, Martin SS, Blumenthal RS. Non-cardiovascular effects associated with statins. BMJ. 2014;349:g3743.
17. Hsu CC,Wang H, Hsu YH, et al. Use of nonsteroidal anti-inflammatory drugs and risk of chronic kidney disease in subjects with hypertension: nationwide longitudinal cohort study. Hypertension. 2015;66(3):524-533.
18. U.S. Food and Drug Administration. FDA drug safety communication: FDA strengthens warning that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes. http://www.fda.gov/Drugs/DrugSafety/ucm451800.htm. Published July 9, 2015. Accessed August 1, 2015.
19. Shah NH, LePendu P, Bauer-Mehren A, et al. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One. 2015;10(6):e0124653. doi: 10.1371/journal.pone.0124653.
20. Leonard CE, Bilker WB, Brensinger CM, et al. Comparative risk of ischemic stroke among users of clopidogrel together with individual proton pump inhibitors. Stroke. 2015;46(3):722-731.
21. Dreischulte T, Morales DR, Bell S, Guthrie B. Combined use of nonsteroidal anti-inflammatory drugs with diuretics and/or renin-angiotensin system inhibitors in the community increases the risk of acute kidney injury. Kidney Int. 2015;88(2): 396-403.
22. Shehab N, Sperling LS, Kegler SR, Budnitz DS. National estimates of emergency department visits for hemorrhage-related adverse events from clopidogrel plus aspirin and from warfarin. Arch Intern Med. 2010;170(21):1926-1933.
23. Lamberts M, Lip GY, Hansen ML, et al. Relation of nonsteroidal anti-inflammatory drugs to serious bleeding and thromboembolism risk in patients with atrial fibrillation receiving antithrombotic therapy: a nationwide cohort study. Ann Intern Med. 2014;161(10):690-698.
24. Schjerning Olsen AM, Gislason GH, McGettigan P, et al. Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy aftermyocardial infarction. JAMA. 2015;313(8):805-814.
25. Kantor ED, Rehm CD, Haas JS, Chan AT, Giovannucci EL. Trends in prescription drug use among adults in the United States from 1999-2012. JAMA. 2015;314(17):1818-1831.
26. O'Muircheartaigh C, English N, Pedlow S, Kwok PK. Sample design, sample augmentation, and estimation forWave 2 of the NSHAP. J Gerontol B Psychol Sci Soc Sci. 2014;69(suppl 2):S15-S26.
27. American Association for Public Opinion Research. Standard Definitions: Final Dispositions of Case Codes and Outcome Rates for Surveys. 5th ed. Lenexa, KS: American Association for Public Opinion Research; 2008.
28. Qato DM, Schumm LP, Johnson M, Mihai A, Lindau ST. Medication data collection and coding in a home-based survey of older adults. J Gerontol B Psychol Sci Soc Sci. 2009;64(suppl 1):i86-i93.
29. National Archive of Computerized Data on Aging. National Social Life, Health, and Aging Project (NSHAP). http://www.icpsr.umich.edu/icpsrweb/NACDA/. Accessed March 2015.
30. Binder DA. On the variances of asymptotically normal estimators from complex surveys. Int Stat Rev. 1983;51:279-292.
31. Graubard BI, Korn EL. Predictive margins with survey data. Biometrics. 1999;55(2):652-659.
32. Wolter KM. Introduction to Variance Estimation. New York, NY: Springer-Verlag; 1985.
33. United States' Census Bureau. Current population survey, annual social and economic supplement, 2012. http://www.census.gov/population/age/data/2012.html. Published December 2013. Accessed November 22, 2015.
34. Basu A, YinW, Alexander GC. Impact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Serv Res. 2010;45(1): 133-151.
35. Introduction: the American Diabetes Association's (ADA) evidence-based practice guidelines, standards, and related recommendations and documents for diabetes care. Diabetes Care. 2012;35(suppl 1):S1-S2.
36. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8) [published correction appears in JAMA. 2014;311(17):1809]. JAMA. 2014;311(5): 507-520.
37. Zhou M, Daubresse M, Stafford RS, Alexander GC. National trends in the ambulatory treatment of hypertension in the United States, 1997-2012. PLoS One. 2015;10(3):e0119292. doi:10.1371/journal.pone.0119292.
38. Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC. Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care. 2014;37(4):985-992.
39. Wang B, Choudhry NK, Gagne JJ, Landon J, Kesselheim AS. Availability and utilization of cardiovascular fixed-dose combination drugs in the United States. Am Heart J. 2015;169(3):379-386.e1. doi:10.1016/j.ahj.2014.12.014.
40. Holtmann G, BigardMA, Malfertheiner P, Pounder R. Guidance on the use of over-the-counter proton pump inhibitors for the treatment of GERD. Int J Clin Pharm. 2011;33(3): 493-500.
41. Guallar E, Stranges S, Mulrow C, Appel LJ, Miller ER III. Enough is enough: stop wasting money on vitamin and mineral supplements. Ann Intern Med. 2013;159(12):850-851.
42. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA. 2012;308(10):1024-1033.
43. Dickens AP, Lang IA, Langa KM, Kos K, Llewellyn DJ. Vitamin D, cognitive dysfunction and dementia in older adults. CNS Drugs. 2011;25(8): 629-639.
44. Moyer VA; U.S. Preventive Services Task Force. Vitamin, mineral, and multivitamin supplements for the primary prevention of cardiovascular disease and cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2014; 160(8):558-564.
45. Stone NJ, Robinson JG, Lichtenstein AH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25) (suppl 2):S1-S45.
46. Doll J, Zeitler E, Becker R. Generic clopidogrel: time to substitute? JAMA. 2013;310(2):145-146.
47. KennallyWC III. Generic atorvastatin and health care costs. N Engl J Med. 2012;366(15):1451.